> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Established for Pfizer’s Trumenba
- URL: https://www.fdaweb.com/regulatory-review-period-established-for-pfizers-trumenba/
- Published: 2016-12-02T12:00:00.000Z
- Updated: 2026-09-14T21:52:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137481

*Federal Register* Notice: FDA has determined the regulatory review period for Pfizer’s meningitis B vaccine Trumenba for patent term extension purposes is 2,079 days. Of this time, 1,943 days occurred during the testing phase of the regulatory review period, while 136 days occurred during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-12-02/pdf/2016-28916.pdf?ref=fdaweb.com).